5. 進行性核上性麻痺 Progressive supranuclear palsy Clinical trials / Disease details


臨床試験数 : 89 薬物数 : 107 - (DrugBank : 40) / 標的遺伝子数 : 65 - 標的パスウェイ数 : 108

  
4 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00382824
(ClinicalTrials.gov)
September 200628/9/2006Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP)Effects of Coenzyme Q10 in Progressive Supranuclear Palsy (PSP): A Multicenter, Randomized, Placebo-controlled, Double Blind StudyProgressive Supranuclear PalsyDietary Supplement: Coenzyme Q10;Other: PlaceboLahey ClinicNULLCompleted30 YearsN/AAll61N/AUnited States
2NCT00328874
(ClinicalTrials.gov)
May 200621/5/2006Study About Safety and Efficacy of Coenzyme Q10 in Progressive Supranuclear PalsyMono-center, Prospective, Double-blind, Placebo-controlled, Randomized Clinical Phase IIa Trial to Assess the Safety, Tolerability, and Immediate Biological Effects of Coenzyme Q10 - nanoQuinon® in Progressive Supranuclear PalsyProgressive Supranuclear PalsyDrug: Coenzyme Q10German Parkinson Study Group (GPS)MSE Pharmazeutika GmbH, Louisenstr.114D-61348 Bad Homburg, Germany;Pitzer Stiftung;Philipps University Marburg Medical CenterCompleted40 Years85 YearsAll20Phase 2Germany
3EUCTR2005-000574-40-DE
(EUCTR)
24/04/200624/01/2006Brain Energy Metabolism in Progressive Supranuclear Palsy: Comparison of PSP Patients and Healthy Controls and Effect of Coenzyme Q10 – nanoQuinon® - N/ABrain Energy Metabolism in Progressive Supranuclear Palsy: Comparison of PSP Patients and Healthy Controls and Effect of Coenzyme Q10 – nanoQuinon® - N/A PSP is a sporadic neurodegenerative disorder resulting in a Parkinson syndrome with postural instability, oculomotor deficits, and cognitive decline. With an average annual incidence of 5.3 / 100000 and an age-adjusted prevalence of 6.4 / 100000, PSP is as common as motor-neuron disease. The progression of PSP is rapid and the median survival after onset of symptoms is 5-10 years. Presently, there is no known effective symptomatic or neuroprotective therapy for PSP.Product Name: Coenzym Q10 Nanodispersion
Product Code: ASK Nr. 21972
INN or Proposed INN: Ubidecarenon
Other descriptive name: Coenzym Q10, Ubiquinon, Ubichinon
Kompetenznetz Parkinson e.V.NULLNot RecruitingFemale: yes
Male: yes
30Germany
4NCT00532571
(ClinicalTrials.gov)
January 200418/9/2007Effects of Coenzyme Q10 in PSP and CBDEffects of Coenzyme Q10 in PSP and CBD, A Randomized, Placebo-Controlled, Double Blind Cross Over Pilot StudyProgressive Supranuclear Palsy;Neurological DisordersDrug: CoQ10Lahey ClinicNULLCompleted40 YearsN/AAllPhase 2/Phase 3United States